Managing the Patent Ductus Arteriosus in the Premature Neonate: A New Look at What We Thought We Knew

Seminars in Perinatology

Volumn 36, Issue 2, 2012, Pages 130-138

  Hammerman, Cathy ^a,b   Bin Nun, Alona ^a   Kaplan, Michael ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Ibuprofen; Indomethacin; Patent ductus arteriosus

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; IBUPROFEN; INDOMETACIN; NITRIC OXIDE; PARACETAMOL; PEROXIDASE; PROSTAGLANDIN; PROSTAGLANDIN E RECEPTOR 4; STEROID; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; BIOCHEMISTRY; BRAIN HEMORRHAGE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; EARLY INTERVENTION; ECHOCARDIOGRAPHY; ENCEPHALOMALACIA; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; HYPOXIA; INFANT FEEDING; LOW DRUG DOSE; NONHUMAN; PATENT DUCTUS ARTERIOSUS; PERSONALIZED MEDICINE; PREMATURITY; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; REVIEW; RISK REDUCTION; THERAPY DELAY;

ACETAMINOPHEN; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DUCTUS ARTERIOSUS, PATENT; ECHOCARDIOGRAPHY; FEMALE; HUMANS; IBUPROFEN; INDIVIDUALIZED MEDICINE; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; MALE; NERVE TISSUE PROTEINS; PREGNANCY; TIME FACTORS;

EID: 84858181964     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2011.09.023     Document Type: Review

References (85)

1. Fowlie P.W. Managing the baby with a patent ductus arteriosus. More questions than answers?. Arch Dis Child Fetal Neonatal Ed 2005, 90:F190.
2. Bose C.L., Laughon M.M. Patent ductus arteriosus: Lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed 2007, 92:F498-F502.
3. Van Overmeire B. Patent ductus arteriosus: How aggressive should we be?. J Neonatol 2007, 91:318.
4. Raval M.V., Laughon M.M., Bose C.L., et al. Patent ductus arteriosus ligation in premature infants: Who really benefits, and at what cost?. J Pediatr Surg 2007, 42:69-75.
5. Hansen T.W. Patency of the ductus arteriosus in the newborn-Now you want it, now you don't. Pediatr Crit Care Med 2007, 8:302-303.
6. Arcilla R.A., Thilenius O.G., Ranniger K. Congestive heart failure from suspected ductal closure in utero. J Pediatr 1969, 75:74-78.
7. Starling M.B., Elliott R.B. The effects of prostaglandins, prostaglandin inhibitors, and oxygen on the closure of the ductus arteriosus, pulmonary arteries, and umbilical vessels in vitro. Prostaglandins 1974, 8:187-203.
8. Sharpe G.L., Thalme B., Larsson K.S. Studies on closure of the ductus arteriosus: Part XI. Ductal closure in utero by a prostaglandin synthetase inhibitor. Prostaglandins 1974, 8:363-368.
9. Coceani F., Olley P.M., Bodach E. Lamb ductus arteriosus: Effect of prostaglandin synthesis inhibitors on the muscle tone and the response to prostaglandin E2. Prostaglandins 1975, 9:299-308.
10. Elliott R.B., Starling M.B., Neutze J.M. Medical manipulation of the ductus arteriosus. Lancet 1975, 1:140-142.
11. Zuckerman H., Reiss U., Rubinstein I. Inhibition of human premature labor by indomethacin. Obstet Gynecol 1974, 44:782-792.
12. Friedman W.F., Hirschklau M.J., Printz M.P., et al. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med 1976, 295:526-529.
13. Heymann M.A., Rudolph A.M., Silverman N.H. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976, 295:530-533.
14. Fowlie P.W., Davis P.G., McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2010, CD000174.
15. Clyman R.I. Recommendations for the postnatal use of indomethacin: An analysis of four separate treatment strategies. J Pediatr 1996, 128:601-607.
16. Van Overmeire B., Van de Broek H., Van Laer P., et al. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 2001, 138:205-211.
17. Lemmers P.M., Toet M.C., van Bel F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. Pediatrics 2008, 121:142-147.
18. Leffler C.W., Busija D.W., Beasley D.G., et al. Maintenance of cerebral circulation during hemorrhagic hypotension in newborn pigs: Role of prostanoids. Circ Res 1986, 59:562-567.
19. Pryds O., Greisen G., Johansen K.H. Indomethacin and cerebral blood flow in premature infants treated for patent ductus arteriosus. Eur J Pediatr 1988, 147:315-316.
20. Laudignon N., Chemtob S., Bard H., et al. Effect of indomethacin on cerebral blood flow velocity of premature newborns. Biol Neonate 1988, 54:254-282.
21. Edwards A.D., Wyatt J.S., Richardson C., et al. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet 1990, 335:1491-1495.
22. Van Bel F., Van De Bor M., Stijnen T., et al. Cerebral blood flow velocity changes in preterm infants after a single dose of indomethacin: Duration of its effects. Pediatrics 1989, 84:802-807.
23. Evans D.H., Levene M.I., Archer L.N. The effect of indomethacin on cerebral blood-flow velocity in premature infants. Dev Med Child Neurol 1987, 29:776-8277.
24. Liem K.D., Hopman J.C., Kollée L.A., et al. Effects of repeated indomethacin administration on cerebral oxygenation and haemodynamics in preterm infants: Combined near infrared spectrophotometry and doppler ultrasound study. Eur J Pediatr 1994, 153:504-509.
25. Van Bel F., Klautz R.J., Steendijk P., et al. The influence of indomethacin on the autoregulatory ability of the cerebral vascular bed in the newborn lamb. Pediatr Res 1993, 34:178-181.
26. Edwards A.D., Wyatt J.S., Richardson C., et al. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet 1990, 335:1491-1495.
27. Keating P., Verhagen E., van Hoften J., et al. Effect of indomethacin infused over 30 minutes on cerebral fractional tissue oxygen extraction in preterm newborns with a patent ductus arteriosus. Neonatology 2010, 98:232-237.
28. Austin N.C., Pairaudeau P.W., Hames T.K., et al. Regional cerebral blood flow velocity changes after indomethacin infusion in preterm infants. Arch Dis Child 1992, 67:851-854.
29. Colditz P., Murphy D., Rolfe P., et al. Effect of infusion rate of indomethacin on cerebrovascular responses in preterm neonates. Arch Dis Child 1989, 64:8-12.
30. Simko A., Mardoum R., Merritt T.A., et al. Effects on cerebral blood flow velocities of slow and rapid infusion of indomethacin. J Perinatol 1994, 14:29-35.
31. Hammerman C., Glaser J., Schimmel M.S., et al. Continuous versus multiple rapid infusions of indomethacin: Effects on cerebral blood flow velocity. Pediatrics 1995, 95:244-248.
32. Christmann V., Liem K.D., Semmekrot B.A., et al. Changes in cerebral, renal and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin. Acta Paediatr 2002, 91:440-446.
33. Sperandio M., Beedgen B., Feneberg R., et al. Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation. Pediatrics 2005, 116:1361-1366.
34. Jegatheesan P., Ianus V., Buchh B., et al. Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: A multicenter, randomized, controlled trial. J Pediatr 2008, 153:183-189.
35. Malviya M., Ohlsson A., Shah S. Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev 2008, CD003951.
36. Hammerman C. Indomethacin and retinopathy of prematurity: The hidden paradox. J Pediatr 2008, 153:587-588.
37. Herrman K., Bose C., Lewis K., et al. Spontaneous closure of the patent ductus arteriosus in very low birth weight infants following discharge from the neonatal unit. Arch Dis Child Fetal Neonatal Ed 2009, 94:F48-F50.
38. Sangem M., Asthana S., Amin S. Multiple courses of indomethacin and neonatal outcomes in premature infants. Pediatr Cardiol 2008, 29:878-884.
39. Hammerman C., Shchors I., Jacobson S., et al. Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: Is the difference in the mode of administration?. Pediatr Res 2008, 64:291-297.
40. Quinn D., Cooper B., Clyman R.I. Factors associated with permanent closure of the ductus arteriosus: A role for prolonged indomethacin therapy. Pediatrics 2002, 110:e10.
41. Hammerman C., Aramburo M.J. Prolonged indomethacin therapy in the prevention of recurrences of patent ductus arteriosus. J Pediatr 1990, 117:771-776.
42. Al Za'abi M., Donovan T., Tudehope D., et al. Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome. Ther Drug Monit 2007, 29:807-814.
43. McNamara P.J., Sehgal A. Towards rational management of the patent ductus arteriosus: The need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007, 92:424-427.
44. Su B.H., Peng C.T., Tsai C.H. Echocardiographic flow pattern of patent ductus arteriosus: A guide to indomethacin treatment in premature infants. Arch Dis Child Fetal Neonatal Ed 1999, 81:F197-F200.
45. Sehgal A., McNamara P.J. Does echocardiography facilitate determination of hemodynamic significance attributable to the ductus arteriosus?. Eur J Pediatr 2009, 168:907-914.
46. Pees C., Walch E., Obladen M., et al. Echocardiography predicts closure of patent ductus arteriosus in response to ibuprofen in infants less than 28 week gestational age. Early Hum Dev 2010, 86:503-508.
47. Flynn P.A., da Graca R.L., Auld P.A., et al. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 2005, 147:38-42.
48. Farombi-Oghuvbu I., Matthews T., Mayne P.D., et al. N-terminal pro-B-type natriuretic peptide: A measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2008, 93:F257-F260.
49. Holmström H., Hall C., Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 2001, 90:184-191.
50. Czernik C., Lemmer J., Metze B., et al. B-type natriuretic peptide to predict ductus intervention in infants <28 weeks. Pediatr Res 2008, 64:286-290.
51. Puddy V.F., Amirmansour C., Williams A.F., et al. Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci 2002, 103:75-77.
52. Chen S., Tacy T., Clyman R. How useful are B-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude?. J Perinatol 2010, 30:780-785.
53. Hsu J.H., Yang S.N., Chen H.L., et al. B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus. J Pediatr 2010, 157:79-84.
54. Attridge J.T., Kaufman D.A., Lim D.S. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2009, 94:F178-F182.
55. Hammerman C., Shchors I., Schimmel M.S., et al. N-terminal-Pro-B-type natriuretic peptide in premature patent ductus arteriosus: A physiologic biomarker, but Is It a clinical tool?. Pediatr Cardiol 2010, 31:62-65.
56. Dagle J.M., Lepp N.T., Cooper M.E., et al. Determination of genetic predisposition to patent ductus arteriosus in preterm infants. Pediatrics 2009, 123:1116-1123.
57. Van Overmeire B., Smets K., Lecoutere D., et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000, 343:674-681.
58. Su B.H., Lin H.C., Chiu H.Y., et al. Comparison of ibuprofen and indomethacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: A randomized controlled trial. Arch Dis Child Fetal Neonatal Ed 2008, 93:F94-F99.
59. Pezzati M., Vangi V., Biagiotti R., et al. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999, 135:733-738.
60. Thomas R.L., Parker G.C., Van Overmeire B., et al. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 2005, 164:135-140.
61. Ohlsson A., Walia R., Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2005, CD003481.
62. Ahlfors C.E. Effect of ibuprofen on bilirubin-albumin binding. J Pediatr 2004, 144:386-388.
63. Cooper-Peel C., Brodersen R., Robertson A. Does ibuprofen affect bilirubin-albumin binding in newborn infant serum?. Pharmacol Toxicol 1996, 79:297-299.
64. Soligard H.T., Nilsen O.G., Bratlid D. Displacement of bilirubin from albumin by ibuprofen in vitro. Pediatr Res 2010, 67:614-618.
65. Diot C., Kibleur Y., Desfrere L. Effect of ibuprofen on bilirubin-albumin binding in vitro at concentrations observed during treatment of patent ductus arteriosus. Early Hum Dev 2010, 86:315-317.
66. Zecca E., Romagnoli C., De Carolis M.P., et al. Does ibuprofen increase neonatal hyperbilirubinemia?. Pediatrics 2009, 124:480-484.
67. Rheinlaender C., Helfenstein D., Walch E., et al. Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants. Acta Paediatr 2009, 98:36-42.
68. Su P.H., Chen J.Y., Su C.M., et al. Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Pediatr Int 2003, 45:665-670.
69. Chamaa N.S., Mosig D., Drukker A., et al. The renal hemodynamic effects of ibuprofen in the newborn rabbit. Pediatr Res 2000, 48:600-605.
70. Cataldi L., Leone R., Moretti U., et al. Potential risk factors for the development of acute renal failure in preterm newborn infants: A case-control study. Arch Dis Child Fetal Neonatal Ed 2005, 90:F514-F519.
71. Murdoch E.M., Sinha A.K., Shanmugalingam S.T., et al. Doppler flow velocimetry in the superior mesenteric artery on the first day of life in preterm infants and the risk of neonatal necrotizing enterocolitis. Pediatrics 2006, 118:1999-2003.
72. Yanowitz T.D., Yao A.C., Pettigrew K.D., et al. Postnatal hemodynamic changes in very-low-birth weight infants. J Appl Physiol 1999, 87:370-380.
73. Patole S.K., Kumaran V., Travadi J.N., et al. Does patent ductus arteriosus affect feed tolerance in preterm neonates?. Arch Dis Child Fetal Neonatal Ed 2007, 92:F53-F55.
74. Dollberg S., Lusky A., Reichman B. Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: A population-based study. J Pediatr Gastroenterol Nutr 2005, 40:184-188.
75. McCurnin D., Clyman R.I. Effects of a patent ductus arteriosus on postprandial mesenteric perfusion in premature baboons. Pediatrics 2008, 122:e1262-e1267.
76. Clyman R.I., Mauray F., Heymann M.A., et al. Cardiovascular effects of patent ductus arteriosus in preterm lambs with respiratory distress. J Pediatr 1987, 111:579-587.
77. Meyers R.L., Alpan G., Lin E., et al. Patent ductus arteriosus and indomethacin and intestinal blood flow and oxygen consumption. Pediatr Res 1990, 29:216A.
78. Coombs R.C., Morgan M.E., Durbin G.M., et al. Gut blood flow velocities in the newborn: Effects of patent ductus arteriosus and parenteral indomethacin. Arch Dis Child 1990, 65:1067-1071.
79. Momma K., Toyoshima K., Takeuchi D., et al. In vivo constriction of the fetal and neonatal ductus arteriosus by a prostanoid EP4-receptor antagonist in rats. Pediatr Res 2005, 58:971-975.
80. Clyman R.I., Seidner S.R., Kajino H., et al. VEGF regulates remodeling during permanent anatomic closure of the ductus arteriosus. Am J Physiol Regul Integr Comp Physiol 2002, 282:R199-R206.
81. Weber S.C., Rheinlaender C., Sarioglu N., et al. The expression of VEGF and its receptors in the human ductus arteriosus. Pediatr Res 2008, 64:340-345.
82. Hammerman C., Bin-Nun A., Markowitz E., et al. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics 2011, 128:e1618-e1621.
83. Grèen K., Drvota V., Vesterqvist O. Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins 1989, 37:311-315.
84. Lucas R., Warner T.D., Vojnovic I., et al. Cellular mechanisms of acetaminophen: Role of cyclooxygenase. FASEB J 2005, 19:635-637.
85. Keller R.L., Tacy T.A., Fields S., et al. Combined treatment with a nonselective nitric oxide synthase inhibitor (l-NMMA) and indomethacin increases ductus constriction in extremely premature newborns. Pediatr Res 2005, 58:1216-1221.